Comerica Bank cut its position in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,155 shares of the company’s stock after selling 1,548 shares during the quarter. Comerica Bank owned 0.07% of Amphastar Pharmaceuticals worth $664,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Quadrant Capital Group LLC acquired a new position in Amphastar Pharmaceuticals during the first quarter worth $53,000. BNP Paribas Arbitrage SA raised its holdings in Amphastar Pharmaceuticals by 52,407.1% during the first quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock worth $150,000 after purchasing an additional 7,337 shares during the last quarter. Sawtooth Solutions LLC acquired a new position in Amphastar Pharmaceuticals during the first quarter worth $215,000. DekaBank Deutsche Girozentrale raised its holdings in Amphastar Pharmaceuticals by 21.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 18,700 shares of the company’s stock worth $344,000 after purchasing an additional 3,300 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Amphastar Pharmaceuticals by 133.4% during the first quarter. SG Americas Securities LLC now owns 18,933 shares of the company’s stock worth $387,000 after purchasing an additional 10,821 shares during the last quarter. 47.26% of the stock is owned by hedge funds and other institutional investors.
In other Amphastar Pharmaceuticals news, SVP Yakob Liawatidewi sold 1,515 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $21.24, for a total transaction of $32,178.60. Following the completion of the sale, the senior vice president now owns 36,670 shares of the company’s stock, valued at $778,870.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jack Y. Zhang sold 300,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $20.82, for a total value of $6,246,000.00. Following the sale, the chief executive officer now directly owns 2,147,316 shares of the company’s stock, valued at approximately $44,707,119.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 339,454 shares of company stock valued at $7,084,842. Company insiders own 30.80% of the company’s stock.
Shares of NASDAQ:AMPH traded down $0.10 during midday trading on Friday, reaching $21.52. The company’s stock had a trading volume of 107,372 shares, compared to its average volume of 266,062. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 102.48 and a beta of 1.17. The company has a quick ratio of 1.83, a current ratio of 2.81 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals Inc has a 1 year low of $17.71 and a 1 year high of $25.43. The business has a 50 day moving average price of $21.12 and a 200 day moving average price of $21.15.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.05. The business had revenue of $79.00 million during the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.03 earnings per share. Sell-side analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.15 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on AMPH shares. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Wednesday, August 7th. BidaskClub downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Wednesday, July 10th. Finally, Wells Fargo & Co set a $29.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $24.64.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Read More: Certificate of Deposit (CD)
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.